{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:22:55Z","timestamp":1781212975171,"version":"3.54.1"},"reference-count":28,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,1]]},"DOI":"10.1210\/jc.2009-2283","type":"journal-article","created":{"date-parts":[[2010,2,16]],"date-time":"2010-02-16T01:45:49Z","timestamp":1266284749000},"page":"1991-1997","source":"Crossref","is-referenced-by-count":261,"title":["Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women"],"prefix":"10.1210","volume":"95","author":[{"given":"Faryal S.","family":"Mirza","sequence":"first","affiliation":[{"name":"University of Connecticut Health Center (F.S.M., L.G.R., J.A.L.), Farmington, Connecticut 06030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Desmond","family":"Padhi","sequence":"additional","affiliation":[{"name":"Amgen (I.D.P.), Thousand Oaks, California 91320-1799"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence G.","family":"Raisz","sequence":"additional","affiliation":[{"name":"University of Connecticut Health Center (F.S.M., L.G.R., J.A.L.), Farmington, Connecticut 06030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"University of Connecticut Health Center (F.S.M., L.G.R., J.A.L.), Farmington, Connecticut 06030"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041114182951500_R1","first-page":"68","article-title":"The frequency of bone disease","author":"Stepnick","year":"2004","journal-title":"In: MacGowan JALGR, Noonan AS, Elderkin AL, eds. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General;"},{"key":"key\n\t\t\t\t2019041114182951500_R2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","article-title":"A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men","volume":"13","author":"Riggs","year":"1998","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114182951500_R3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","article-title":"Wnt\/\u03b2-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis","volume":"8","author":"Day","year":"2005","journal-title":"Dev Cell"},{"key":"key\n\t\t\t\t2019041114182951500_R4","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1359\/jbmr.2003.18.10.1842","article-title":"BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop","volume":"18","author":"Rawadi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114182951500_R5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11914-007-0006-0","article-title":"Wnt signaling and the regulation of bone mass","volume":"5","author":"Baron","year":"2007","journal-title":"Curr Osteoporos Rep"},{"key":"key\n\t\t\t\t2019041114182951500_R6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.14310\/horm.2002.1111024","article-title":"The role of the Wnt signaling pathway in osteoblast commitment and differentiation","volume":"6","author":"Yavropoulou","year":"2007","journal-title":"Hormones (Athens)"},{"key":"key\n\t\t\t\t2019041114182951500_R7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/\u03b2-catenin signaling in development and disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019041114182951500_R8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/BOR.0b013e32816e06f9","article-title":"The Wnt signaling pathway and bone metabolism","volume":"19","author":"Johnson","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"key\n\t\t\t\t2019041114182951500_R9","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","article-title":"Wnt signalling in osteoblasts regulates expression of the receptor activator of NF\u03baB ligand and inhibits osteoclastogenesis in vitro","volume":"119","author":"Spencer","year":"2006","journal-title":"J Cell Sci"},{"key":"key\n\t\t\t\t2019041114182951500_R10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1242\/dev.01117","article-title":"LDL receptor-related proteins 5 and 6 in Wnt\/\u03b2-catenin signaling: arrows point the way","volume":"131","author":"He","year":"2004","journal-title":"Development"},{"key":"key\n\t\t\t\t2019041114182951500_R11","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Seme\u0308nov","year":"2005","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041114182951500_R12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114182951500_R13","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041114182951500_R14","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","article-title":"Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation","volume":"35","author":"Sutherland","year":"2004","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114182951500_R15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114182951500_R16","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t2019041114182951500_R17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet"},{"key":"key\n\t\t\t\t2019041114182951500_R18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet"},{"key":"key\n\t\t\t\t2019041114182951500_R19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"Bezooijen","year":"2004","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019041114182951500_R20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.33.3.267","article-title":"Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship","volume":"33","author":"Stein","year":"1983","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041114182951500_R21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"key\n\t\t\t\t2019041114182951500_R22","first-page":"1162","article-title":"Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength","volume":"21","author":"Ominsky","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"Suppl 37","key":"key\n\t\t\t\t2019041114182951500_R23","article-title":"Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women","volume":"22","author":"Padhi","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114182951500_R24","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114182951500_R25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0026-0495(76)90133-5","article-title":"The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part III of IV parts; PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism","volume":"25","author":"Parfitt","year":"1976","journal-title":"Metabolism"},{"key":"key\n\t\t\t\t2019041114182951500_R26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/8756-3282(86)90020-7","article-title":"Trabecular bone remodeling and balance in primary hyperparathyroidism","volume":"7","author":"Eriksen","year":"1986","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114182951500_R27","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041114182951500_R28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/4\/1991\/10780809\/jcem1991.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T00:10:33Z","timestamp":1558829433000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/95\/4\/1991\/2597656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-2283","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,1]]}}}